BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
The stocks founds in the One Hot Stock category use stocks that are in long term, short term trends and are early in the buy signal trend. Suggested buy prices are listed with a price “or better”. Or better means anything lower than the buy price listed. (Learn about order types here). This is a confirmation strategy that waits for the stock to make a move then a trader enters the trend at specific prices. In many cases stocks that are in up trends tend to continue the overall trend direction and the prior trend is the path of least resistance. To learn more about trend following as well as reversal strategies you can go here.
